Impact	O
of	O
Revised	O
Broad	B:C3536856
-	I:C3536856
Spectrum	I:C3536856
Cephalosporin	I:C3536856
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
Breakpoints	O
on	O
Susceptibility	O
in	O
Enterobacteriaceae	O
Producing	O
AmpC	O
β-	I:C0164503
Lactamase	I:C0164503
.	O

Impact	O
of	O
Revised	O
Broad	O
-	I:C3536856
Spectrum	I:C3536856
Cephalosporin	I:C3536856
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
Breakpoints	O
on	O
Susceptibility	O
in	O
Enterobacteriaceae	O
Producing	O
AmpC	O
β-	I:C0164503
Lactamase	I:C0164503
.	O

Impact	O
of	O
Revised	O
Broad	O
-	I:C3536856
Spectrum	I:C3536856
Cephalosporin	I:C3536856
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
Breakpoints	B:C2713357
on	O
Susceptibility	O
in	O
Enterobacteriaceae	O
Producing	O
AmpC	O
β-	I:C0164503
Lactamase	I:C0164503
.	O

Impact	O
of	O
Revised	O
Broad	O
-	I:C3536856
Spectrum	I:C3536856
Cephalosporin	I:C3536856
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
Breakpoints	O
on	O
Susceptibility	O
in	O
Enterobacteriaceae	B:C0014346
Producing	O
AmpC	O
β-	I:C0164503
Lactamase	I:C0164503
.	O

Impact	O
of	O
Revised	O
Broad	O
-	I:C3536856
Spectrum	I:C3536856
Cephalosporin	I:C3536856
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
Breakpoints	O
on	O
Susceptibility	O
in	O
Enterobacteriaceae	O
Producing	O
AmpC	B:C0164503
β-	I:C0164503
Lactamase	I:C0164503
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	B:C2713357
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	B:C3536856
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	B:C3536856
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	B:C1764827
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	B:C1295792
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	B:C0036766
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	B:C0085483
freundii	I:C0085483
,	O
and	O
Morganella	O
morganii	I:C0315276
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
(	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
)	O
breakpoints	O
for	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
(	O
broad	O
-	I:C3536856
spectrum	I:C3536856
cephalosporins	I:C3536856
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	I:C1295792
,	O
Serratia	O
marcescens	I:C0036766
,	O
Citrobacter	O
freundii	I:C0085483
,	O
and	O
Morganella	B:C0315276
morganii	I:C0315276
.	O

The	O
2011	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefotaxime	O
and	O
ceftazidime	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
by	O
2.9	O
%	O
and	O
5.9	O
%	O
,	O
respectively	O
.	O

The	O
2011	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefotaxime	B:C0007554
and	O
ceftazidime	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
by	O
2.9	O
%	O
and	O
5.9	O
%	O
,	O
respectively	O
.	O

The	O
2011	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefotaxime	O
and	O
ceftazidime	B:C0007559
reduced	O
the	O
rates	O
of	O
susceptibility	O
by	O
2.9	O
%	O
and	O
5.9	O
%	O
,	O
respectively	O
.	O

The	O
2014	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	O
.	O

The	O
2014	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	B:C0055003
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	O
.	O

The	O
2014	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	B:C1764827
as	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	O
.	O

The	O
2014	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible	B:C2827754
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	O
.	O

The	O
2014	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	B:C2827754
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	O
.	O

The	O
2014	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
(	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
)	O
for	O
cefepime	B:C0055003
.	O

Among	O
183	O
isolates	B:C1764827
with	O
extended	O
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	O
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

Among	O
183	O
isolates	O
with	O
extended	B:C0164503
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	O
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

Among	O
183	O
isolates	O
with	O
extended	O
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	B:C0164503
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	O
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

Among	O
183	O
isolates	O
with	O
extended	O
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	B:C0007554
,	O
ceftazidime	O
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

Among	O
183	O
isolates	O
with	O
extended	O
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	B:C0007559
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

Among	O
183	O
isolates	O
with	O
extended	O
-	I:C0164503
spectrum	I:C0164503
β-	I:C0164503
lactamase	I:C0164503
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	O
,	O
and	O
cefepime	B:C0055003
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

The	O
proportion	O
of	O
ESBL	B:C0164503
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	B:C3536856
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	B:C1764827
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	B:C0007554
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	B:C0007559
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	B:C0055003
)	O
.	O

In	O
summary	O
,	O
implementation	O
of	O
new	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
led	O
to	O
little	O
change	O
in	O
susceptibility	O
to	O
cefotaxime	O
and	O
ceftazidime	O
but	O
a	O
substantial	O
change	O
in	O
susceptibility	O
to	O
cefepime	O
.	O

In	O
summary	O
,	O
implementation	O
of	O
new	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
led	O
to	O
little	O
change	O
in	O
susceptibility	O
to	O
cefotaxime	B:C0007554
and	O
ceftazidime	O
but	O
a	O
substantial	O
change	O
in	O
susceptibility	O
to	O
cefepime	O
.	O

In	O
summary	O
,	O
implementation	O
of	O
new	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
led	O
to	O
little	O
change	O
in	O
susceptibility	O
to	O
cefotaxime	O
and	O
ceftazidime	B:C0007559
but	O
a	O
substantial	O
change	O
in	O
susceptibility	O
to	O
cefepime	O
.	O

In	O
summary	O
,	O
implementation	O
of	O
new	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
led	O
to	O
little	O
change	O
in	O
susceptibility	O
to	O
cefotaxime	O
and	O
ceftazidime	O
but	O
a	O
substantial	O
change	O
in	O
susceptibility	O
to	O
cefepime	B:C0055003
.	O

The	O
recognition	B:C0524637
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	O
and	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

The	O
recognition	O
of	O
revised	O
Clinical	B:C1274109
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	O
and	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

The	O
recognition	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	B:C3536856
and	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

The	O
recognition	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	O
and	O
susceptible	B:C2827754
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

The	O
recognition	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	O
and	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	B:C0871685
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

The	O
recognition	O
of	O
revised	O
Clinical	O
and	I:C1274109
Laboratory	I:C1274109
Standards	I:C1274109
Institute	I:C1274109
criteria	O
for	O
BSC	O
and	O
susceptible	O
-	I:C2827754
dose	I:C2827754
dependent	I:C2827754
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	B:C0003232
and	O
dosing	O
regimen	O
.	O

